α-干扰素联合苦参素治疗HBeAg阳性慢性乙型肝炎疗效观察

doi:10.3969/j.issn.1672-5069.2014.02.019

Abstract

Li Weihong.. Interferon-α and matrine in the treatment of patients with HbeAg-positive hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(2): 186-187.

[1] Chan HL，Wang H，Niu J，et al. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B:A double-blind，placebo-controlled trial. Antiviral Ther，2007，12（3）:345-353.
[2] Lau GK，Marcellin P，Brunetto M，et al. On-treatment monitoring of HBsAg levels to predict response to peginterferon alfa-2a in patients with HBeAg-positive chronic hepatitis. J Hepatol，2009，50:S333.
[3] Lau GK，Piratvisuth T，Luo KX，et al. Peginterferon alfa-2a， lamivudine，and the combination for HBeAg-positive chronic hepatitis B.N Engl J Med，2005，352:2682-2695.
[4] Li CQ，Zhu YT，Zhang FX，et al. Anti-HBV effect of liposome-encapsulated matrine in vitro and in vivo. World J Gastroenterol，2005，11（3）:426-428.
[5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志，2011，14（2）：81-89.
[6] Long Y，Lin XT，Zeng KL，et al. Efficacy of intramuscular matrine in the treatment of chronic hepatitis B. Hepatobiliary Pancreat Dis Int，2004，3（1）:69-72.
[7] Wang XP，Yang RM. Movement disorders possibly induced by traditional Chinese herbs. Eur Neurol， 2003，50（3）:153-159.
[8] Liu J， Zhu M，Shi R，et al. Radix Sophorae flavescentis for chronic hepatitis B:a systematic review of randomized trials. Am J Chin Med，2003，31（3）:337-354.
[9] 陈从新，刘波，马勇，等. 拉米夫定和干扰素α及苦参碱防治乙型肝炎肝衰竭生存者的肝纤维化进展.中华肝脏病杂志，2009，17（7）：505-508.
[10] Moucari R，Mackiewicz V，Lada Oet al. Early serum HBsAg drop:a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology，2009，49:1151-1157.
[11] Lau G，Marcellin P，Peters M. Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies. Hepatol Int，2007，1（2）:316-325.
[12] Yuen MF. Revisiting the natural history of chronic hepatitis B:impact of new concepts on clinical management. J Gastroenterol Hepatol，2007，22（7）:973-976.
[13] Fried MW，Piratvisuth T，Lau GK，et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology，2008，47（2）:428-434.
[14] Tangkijvanich P，Komolmit P，Mahachai V，et al. Comparison between quantitative hepatitis B surface antigen，hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. Hepatol Res，2010，40（4）: 269-277.

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.

Interferon-α and matrine in the treatment of patients with HbeAg-positive hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments